NovaQuest Capital Management, an investor in life sciences and healthcare, has announced a $20m product financing agreement with Mileutis, an Israeli biopharmaceutical company, to help mitigate the use of antibiotics in animals. NovaQuest’s investment will drive the continued development and commercialisation of Mileutis’ novel, biologically sourced, and residue-free therapies for animal health. NovaQuest’s investment is its first ever in the animal health care field and in an Israeli company.